Truist initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and $41 price target The firm, which thinks Viridian is well-positioned following veligrotug’s BLA submission and potential launch in thyroid eye disease, notes that its valuation is driven by veligrotug.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics
- Viridian Therapeutics Advances Toward Profitability with Strategic Moves
- Viridian Therapeutics price target raised to $45 from $41 at RBC Capital
- Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs
- Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability